Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
McKinsey
AstraZeneca
Dow
Moodys

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,731,986

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,731,986
Title:Therapeutic foam
Abstract: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimising the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.
Inventor(s): Wright; David Dakin Iorwerth (Buckinghamshire, GB), Harman; Anthony David (Oxfordshire, GB), Robinson; Nikki (Uxbridge, GB), Hodges; Garry (Middlesex, GB), Kadar; Adil (Middlesex, GB), Moggridge; Geoffrey D. (Cambridge, GB), Van Liew; Hugh (Barnstable, MA)
Assignee: BTG International Ltd. (London, GB)
Application Number:10/522,527
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,731,986

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y Y A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,731,986

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0326768.9Nov 17, 2003
United Kingdom0422307.9Oct 7, 2004
PCT Information
PCT FiledNovember 17, 2004PCT Application Number:PCT/GB2004/004848
PCT Publication Date:June 02, 2005PCT Publication Number: WO2005/048977

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Harvard Business School
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.